Pfizer ranked as Asia’s leading company for covid-19 response and patient-centric approach by Asian patient groups


  • Post by :
  • Source: PA
  • Date: August 26, 2022

SINGAPORE, AUGUST 26, 2022 – Pfizer has been ranked first for its Covid-19 response, patient focus, patient safety and delivery of innovative, high-quality products among pharmaceutical companies in Asia in the “Corporate Reputation of Pharma” led by patient groups across the APAC region. Overall, the company is ranked second for corporate reputation in Asian countries.

Pfizer rose from 4th place in the survey rankings to take the top spot in terms of patient groups “working” with Pfizer, representing a significant ranking increase in 2021 compared to 2020, across ten Asian countries.
This survey, conducted by the British company PatientView, measures various aspects of the performance of the pharmaceutical industry in terms of corporate reputation, again from the perspective of the patient. The patient groups responding to this survey work across all therapeutic areas and are uniquely positioned to comment on the pharmaceutical industry’s performance during the pandemic.

Opinions of 300 patient groups were collected on the performance of the pharmaceutical industry in 2021. These Asian patient groups had collectively been in communication with nearly 2.7 million Asian patients in 2021. In total, 31 pharmaceutical companies were assessed by Asian patient groups in 2021. Asia edition of this annual survey.

  • Pfizer is ranked 1st in the Australia/New Zealand region and globally 2n/a in Asia in its corporate reputation from a patient perspective

  • Asian patient groups placed the pharmaceutical industry 1st for the company’s reputation in Asia among other healthcare sectors

Asian patient groups familiar with and/or working with Pfizer rated the company significantly improved its scores on all corporate reputation indicators in 2021.

Pharma’s performance in creating (and then delivering) high-speed vaccines in response to the Covid-19 pandemic convinced most Asian patient groups responding in 2021 of the industry’s effectiveness and the company both in terms of innovation and the ability to deliver products that truly benefit patients.

“Patients are our North Star. From the first stage of drug development through the final approval and use of our medicines and vaccines, our goal is to achieve breakthroughs that change the lives of patients. We work with and for patients, advocates and caregivers to meet the changing needs of patients everywhere. Pfizer colleagues collaborate with patients and patient advocates to develop breakthrough treatments and innovative approaches to help address patient challenges. These partnerships have helped increase patient engagement in research and development, diversify clinical trials, develop patient-friendly educational materials and patient support programs, and elevate priority policy and health issues. social impact. Patients are at the center of everything we do. Everything we do is aimed at helping patients around the world live longer, healthier lives,” said Mr. Anil Argilla, President, Emerging Markets Asia, Pfizer Biopharmaceuticals Group, Pfizer Inc.

PatientView has published the results of its latest ‘Corporate Reputation of Pharma’ survey – Asia 2021 edition, the detailed report can be accessed at the following link: 08/PATIENTVIEW-PRESS-RELEASE-CORP-REP-Asia-final.pdf. PatientView is a UK-based research, publishing and consultancy group, established on the belief that patients’ opinions should be taken into account in all important healthcare decisions.


About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring people therapies that dramatically extend and improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of healthcare products, including innovative medicines and vaccines. Every day, Pfizer colleagues work in developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. In line with our responsibility as one of the world’s leading innovative biopharmaceutical companies, we work with healthcare providers, governments and local communities to support and expand access to reliable and affordable healthcare in the whole world. For over 170 years, we’ve worked to make a difference for everyone who counts on us.

Comments are closed.